UY26071A1 - Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp - Google Patents

Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp

Info

Publication number
UY26071A1
UY26071A1 UY26071A UY26071A UY26071A1 UY 26071 A1 UY26071 A1 UY 26071A1 UY 26071 A UY26071 A UY 26071A UY 26071 A UY26071 A UY 26071A UY 26071 A1 UY26071 A1 UY 26071A1
Authority
UY
Uruguay
Prior art keywords
nitrogen
formula
pharmaceutically acceptable
pyridypiridazine
inhibitors
Prior art date
Application number
UY26071A
Other languages
English (en)
Inventor
Guixue Yu
John Macor
Hyei-Jha Chung
Michael Humora
Kishta Katipally
Soojin Kim
Yizhe Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26071A1 publication Critical patent/UY26071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Un compuesto de la fórmula I (como: 1-(9-cloro-3-etil-3H-pirazolo[4',3':5,6]pirido[3,4-d]piridaxin-6-il)-4-piperidinol), que incluye una sal del mismo, farmacéuticamente aceptable caracterizado porque Y es nitrogeno ó C(R5); Z en nitrogeno ó C(R6) siempre que al memos una de Y ó Z sea nitrogeno; R1 y R2 se seleccionan independientemente entre Cl, SR7, OR7, NR8R9; R3 es hidrogeno, alquilo, arilalquilo los cuales pueden estar sustituidos; R4 es hidrogeno, halogeno, alquilo sustituido o no. Una composición farmacéutica caracterizada por que comprende uno o más compuestos, que incluyen una sal del mismo, farmacéuticamente aceptable y un portador farmacéuticamente aceptable. Un método de tratamiento de una condición asociada a cGMP, al tratamiento de una alteración cardiovascular, de la disfunción sexual, que comprende administrar a un mamifero en necesidad del mismo, de una cantidad efectiva de una composición de fórmulal l. Estos compuestos de fórmula l son empleados como inhibidores de la cGMP PDE especialmente del tipo V. Ver proceso en Reiv.
UY26071A 1999-03-22 2000-03-22 Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp UY26071A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12548899P 1999-03-22 1999-03-22
US14800999P 1999-08-10 1999-08-10

Publications (1)

Publication Number Publication Date
UY26071A1 true UY26071A1 (es) 2000-10-31

Family

ID=26823624

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26071A UY26071A1 (es) 1999-03-22 2000-03-22 Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp

Country Status (10)

Country Link
US (1) US6316438B1 (es)
EP (1) EP1165521A4 (es)
JP (1) JP2002540102A (es)
KR (1) KR20020015030A (es)
CN (1) CN1161341C (es)
AU (1) AU765128B2 (es)
CA (1) CA2368023A1 (es)
ID (1) ID30182A (es)
UY (1) UY26071A1 (es)
WO (1) WO2000056719A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU4663100A (en) * 1999-04-30 2000-11-17 Lilly Icos Llc Treatment of female arousal disorder
WO2002013798A2 (en) * 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
EP3342420A1 (en) * 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US7829720B2 (en) 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) * 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
ES2433661T3 (es) 2005-04-19 2013-12-12 Takeda Gmbh Roflumilast para el tratamiento de hipertensión pulmonar
AU2008268627A1 (en) * 2007-06-22 2008-12-31 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20100178340A1 (en) * 2007-06-22 2010-07-15 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
MX2009013461A (es) * 2007-06-22 2010-01-15 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
SI2170292T1 (sl) * 2007-06-22 2014-05-30 Bristol-Myers Squibb Holdings Ireland Tabletirani sestavki, ki vsebujejo atazanavir
CA2706866A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
CA2756810A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Pyrazolo-pyrrolopyridine-dione derivatives useful in the treatment of cancer
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US20170044091A1 (en) 2014-04-30 2017-02-16 Air Water Inc. Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN108395377A (zh) * 2018-01-16 2018-08-14 吴江信凯医药科技有限公司 一种3-氯-4-甲氧基苄胺盐酸盐的制备方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669950A (en) 1970-12-01 1972-06-13 Squibb & Sons Inc DIPYRAZOLO{8 3,4-b:3,4d{9 -PYRIDIN-3-ONES
US3787430A (en) 1972-07-13 1974-01-22 Squibb & Sons Inc Derivatives of dipyrazolo(3,4-b;3',4'-d)pyridines
US4072681A (en) 1977-03-02 1978-02-07 E. R. Squibb & Sons, Inc. 3,7-Dihydro- and 1,7-dihydro-4H-pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-4-ones
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
CA2056142A1 (en) 1990-11-27 1992-05-28 Hirotomo Masuya Pyridopyridazine compounds and their use
JP3477651B2 (ja) * 1993-01-28 2003-12-10 武田薬品工業株式会社 スーパーオキシドラジカルの検出・定量法
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5849741A (en) * 1994-08-09 1998-12-15 Eisai Co., Ltd. Fused pyridazine compounds
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
JPH08143558A (ja) * 1994-11-21 1996-06-04 Fujisawa Pharmaceut Co Ltd アミノピペラジン誘導体の新規医薬用途
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5488055A (en) * 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
US5614530A (en) * 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
CA2258079A1 (en) * 1996-08-20 1998-02-26 Mayu Shibazaki Remedy for erection failure comprising fused pyridazine compound
JPH10114657A (ja) * 1996-08-20 1998-05-06 Eisai Co Ltd 縮合ピリダジン系化合物の勃起機能不全症治療剤
US5874437A (en) 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
AU7553198A (en) * 1997-06-12 1998-12-30 Sumitomo Pharmaceuticals Company, Limited Pyrazole derivatives
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
AU765128B2 (en) 2003-09-11
AU3732700A (en) 2000-10-09
ID30182A (id) 2001-11-08
CN1161341C (zh) 2004-08-11
WO2000056719A1 (en) 2000-09-28
KR20020015030A (ko) 2002-02-27
US6316438B1 (en) 2001-11-13
CA2368023A1 (en) 2000-09-28
EP1165521A1 (en) 2002-01-02
EP1165521A4 (en) 2002-05-22
CN1344257A (zh) 2002-04-10
JP2002540102A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
UY26071A1 (es) Inhibidores fusionados de piridopiridazina de fosfodiesterasa de cgmp
MXPA04002423A (es) Derivados de piperazina con actividad antagonista del receptor ccr1.
HUP0203874A2 (hu) Helyettesített 4-(fenil-N-alkil)piperazin és piperidinszármazékok és alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
DE602004016516D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
CO5580774A2 (es) Derivados de quinazolina como agentes antineoplasicos
CO5690130A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc
HUP0203872A2 (hu) Helyettesített 4-(fenil-N-alkil)-piperazin és piperidinszármazékok, alkalmazásuk dopamin neurotranszmissziós modulátorként és ezeket tartalmazó gyógyszerkészítmények
AR006906A1 (es) Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO4950557A1 (es) Compuestos y metodos
AR016433A1 (es) Procedimiento para el tratamiento de la impotencia y composiciones.
MX341474B (es) Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 ( pde4).
MY107756A (en) Piperazine derivatives.
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos
SG143011A1 (en) Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
MXPA02011426A (es) Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa.
EA200101223A1 (ru) Новые соединения, их применение и получение
DE602004020638D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
PE20020469A1 (es) Policiclicos nucleotidicos como inhibidores de xantina fosfodiesterasa v
CO4650042A1 (es) Derivados de 6-fenilpiridil-2-amina
CA2339630A1 (en) Carboline derivatives as cgmp phosphodiesterase inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20091022